Abstract Number: 494 • 2019 ACR/ARP Annual Meeting
Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
Background/Purpose: The Targeting Immune Responses for Prevention of RA (TIP-RA) Collaborative prospectively studies individuals at high risk for developing RA because of serum ACPA positivity…Abstract Number: 537 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…Abstract Number: 842 • 2019 ACR/ARP Annual Meeting
Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease
Background/Purpose: The frequency of pulmonary involvement in rheumatoid arthritis varies between 7-35%. The most important cause of death in RA patients is lung disease in…Abstract Number: 960 • 2019 ACR/ARP Annual Meeting
Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are the main diagnostic and pathologic autoantibodies in rheumatoid arthritis. However, autoantibodies develop against proteins with…Abstract Number: 1172 • 2019 ACR/ARP Annual Meeting
The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging
Background/Purpose: Many RA patients in clinical remission have evidence of bone marrow edema (BME) on magnetic resonance imaging (MRI), with radiographic bone damage progression appearing…Abstract Number: 1344 • 2019 ACR/ARP Annual Meeting
Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) diseases. Dyslipidemia is a known adverse reaction to tocilizumab (TCZ). TNFa blockade…Abstract Number: 1371 • 2019 ACR/ARP Annual Meeting
Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)
Background/Purpose: Daily health care deals with a wide spectrum of RA patients from statuses of remission (R) to disease activities at low (L), moderate (M)…Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting
Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting
Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…Abstract Number: 1888 • 2019 ACR/ARP Annual Meeting
Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
Background/Purpose: The ability to accurately predict whether RA patients will flare following DMARD-tapering would open doors in clinical decision-making for achieving drug-free remission (DFR). Calprotectin…Abstract Number: 2003 • 2019 ACR/ARP Annual Meeting
Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5
Background/Purpose: Anti-polygalacturonic acid antibody (PGA-Ab) is a new rheumatoid arthritis (RA)-related autoantibody first identified by our group. The sensitivity and specificity of PGA-Ab is even…Abstract Number: 2159 • 2019 ACR/ARP Annual Meeting
Pachymeningitis in Rheumatic Disease
Background/Purpose: Pachymeningitis is a rare complication of rheumatic disease. Patients present with hearing loss or other neurologic complications. Diagnosis is made by thickening of dura…Abstract Number: 2300 • 2019 ACR/ARP Annual Meeting
Risk Factors for Transfusion and Use of Tranexemic Acid in Patients with Rheumatoid Arthritis Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty
Background/Purpose: Utilization of total hip (THA) and total knee arthroplasty (THA) remains high for patients with RA, and most patients have moderate to high disease…Abstract Number: 2322 • 2019 ACR/ARP Annual Meeting
Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness
Background/Purpose: Both traditional cardiovascular (CV) risk factors and disease-related factors contribute to the increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). Mechanisms of…Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 56
- Next Page »